ArticleRenal failure2026
Kidney function decline and kidney stone risk: cohort and Mendelian randomization analyses.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the association and potential causal effect of kidney function decline on kidney stone disease (KSD).
methodsWe evaluated linear and non-linear associations between kidney function decline-assessed by estimated glomerular filtration rate (eGFR) and chronic kidney disease (CKD)-and KSD using individual-level data from the UK Biobank and summary genome-wide association study (GWAS) data. Analyses included prospective cohort models, one-sample Mendelian randomization (MR), two-sample MR, genetic correlation analyses, and identification of shared single-nucleotide polymorphisms (SNPs).
resultsIndividuals with lower baseline eGFR_cys had an increased risk of KSD during a mean follow-up of 13.9 years. However, longitudinal decline in eGFR over time (ΔeGFR_cys) was associated with a reduced risk of KSD (HR 0.80, 95% CI 0.67-0.95). Mendelian randomization analyses showed that genetically predicted lower eGFR (one-sample: OR 0.70, 95% CI 0.63-0.78; two-sample: OR 0.78, 95% CI 0.71-0.85) and CKD (one-sample: OR 0.73, 95% CI 0.65-0.81; two-sample: OR 0.89, 95% CI 0.83-0.97) were associated with a lower risk of KSD. Genetic correlation analyses suggested shared genetic influences between kidney function traits and KSD (eGFR: r
conclusionsKidney function decline appears to be associated with a reduced risk of KSD. Combined observational and genetic analyses support shared biological pathways linking these conditions, although further studies are needed to clarify the underlying mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.